Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy
- PMID: 37830359
- DOI: 10.1080/17474086.2023.2271170
Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy
Keywords: CLL; Efficacy; Net clinical Benefit; Quality of Life; Safety; Targeted Agents.
Comment on
-
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources